Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug	Cisplatin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	small cell lung cancer
ICD-0-3	C56.9
Methods	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc.
Sample	SCLC tissues, SCLC cell lines NCI-H69, NCI-H446, and the drugresistant H69AR, Cisplatin-resistant NCIH446DDP
Expression Pattern	up-regulated
Function Description	Linc00173 was highly expressed in SCLC chemoresistant cell lines, and promoted SCLC cells chemoresistance, proliferation, and migrationinvasion. Animal studies validated that Linc00173 induced tumor chemoresistance and growth of SCLC in vivo. Moreover, Linc00173 upregulated Etk through functioning as a competitive endogenous RNA (ceRNA) by sponging miRNA-218 and led to the upregulation of GSKIP and NDRG1, resulting in the translocation of ?-catenin. Importantly, expression analysis revealed that both Linc00173 and Etk were upregulated in SCLC patient samples and exhibiting positive Linc00173/Etk correlation. High expression of Linc00173 closely correlated with chemoresistance, extensive stage, and shorter survival in SCLC patients. Collectively, our study illustrated a Linc00173-mediated process that facilitated chemoresistance and progression in SCLC, which might provide treatment strategy against SCLC.
Pubmed ID	31477834
Year	2019
Title	Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression

External Links